Zürcher Kantonalbank has disclosed a stake in Avadel Pharmaceuticals plc, a move tracked under the Irish Takeover Panel Act of 1997. The latest data used for this filing is dated January 14, 2026.
The bank and its subsidiaries currently hold 37,707 ordinary shares of Avadel Pharmaceuticals, representing 0.04% of the company’s relevant securities. This disclosure specifically excludes any derivative activities or transactions involving other parties perhaps making an offer for the company.
Zürcher Kantonalbank’s reported stake in Avadel Pharmaceuticals is a standard disclosure required by Irish regulations when an entity acquires 0.04% or more of a company’s voting rights. The bank’s investment, totaling 37,707 ordinary shares as of January 14, 2026, does not currently indicate any intention to launch a takeover bid, as the filing explicitly excludes any related derivative transactions or collaborations with potential offerors. The purpose of the disclosure is to provide transparency to the market regarding potential changes in ownership.
The filing with the Irish Takeover Panel confirms this is a standard Rule 8.3 disclosure, meaning no agreements, inducements, or understandings regarding indemnity or options were reported. Notably, a Supplemental Form 8, which would detail further specifics, was not included with this report, suggesting a straightforward ownership position. The situation remains static as of the filing date, with no indication of further action planned by Zürcher Kantonalbank.
